Evidence map›Paper›PMID 35393089›Full record

ArticleJournal de medecine vasculaire2022

Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study.

A F Guédon, A Delarue, N Mohamedi, A Roffé, L Khider, N Gendron, G Goudot, G Détriché, R Chocron, S Oudard and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal de medecine vasculaire, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A F GuédonVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France. Electronic address: emmanuel.messas@aphp.fr.
A DelarueVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France.
N MohamediVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France.
A RofféVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France.
L KhiderVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France; UMR 970 PARCC Inserm, Paris University, Paris, France.
N GendronUniversité de Paris, Innovative Therapies in Hemostasis, Inserm, 75006 Paris, France.
G GoudotVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France; UMR 970 PARCC Inserm, Paris University, Paris, France.
G DétrichéVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France; UMR 970 PARCC Inserm, Paris University, Paris, France.
R ChocronUMR 970 PARCC Inserm, Paris University, Paris, France; Emergency department, AP-HP, Paris University, Paris, France.
S OudardOncology department, AP-HP, Paris University, Paris, France.
D M SmadjaUniversité de Paris, Innovative Therapies in Hemostasis, Inserm, 75006 Paris, France; Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015 Paris, France.
T MiraultVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France; UMR 970 PARCC Inserm, Paris University, Paris, France.
E MessasVascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France; UMR 970 PARCC Inserm, Paris University, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 uses Angiotensin-Converting Enzyme 2 as a viral gateway to the cell and could interact with the renin-angiotensin-aldosterone system. Other studies have shown kalemia abnormalities in patients with severe forms of coronavirus disease 2019. Our goal was to assess the prognosis value of kalemia within ten days of symptom offset in the COVID-19 hospitalized population.

methodsWe analyzed data from a prospective cohort that included 65 patients with COVID-19, admitted between March 15, 2020, and March 21, 2020. The study aimed at determining the relationship between baseline kalemia and the admission to an intensive care unit (ICU) or death.

resultsThe median age of the patients was 65 [54-79] years old, and 66.2% of the patients were men. Baseline kalemia under 3.8mmol/l occurred in 31 patients (48%), including 11 patients (35.5%) who were admitted to an ICU and one patient (3.2%) who died before ICU admission. In the primary end-point analysis, the adjusted hazard ratios for admission to an ICU or death were 3.52 [95% confidence interval (CI), 1.12 to 11.04] among patients with low baseline kalemia.

conclusionOur study suggests that low kalemia levels within ten days of the first symptom onset might be associated with an increased risk of intensive care unit admission or death. The future perspective should be to better understand this relationship.

Indexed as

COVID-19AgedCohort StudiesHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesSARS-CoV-2CoronavirusCOVID-19HypokalemiaICUPrognosisSARS-CoV-2

Identifiers

PMID35393089
PMCPMC8557982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.